HealthDay News — Tamsulosin does not significantly increase the urinary stone passage rate compared with placebo, according to a study published online June 18 in JAMA Internal Medicine.
Andrew C. Meltzer, MD, from the George Washington University School of Medicine & Health Sciences in Washington, D.C., and colleagues randomized 512 patients presenting in an emergency department with symptomatic urinary stone in the ureter (<9mm in diameter) to treatment with either tamsulosin (0.4mg) or placebo daily for 28 days.
The researchers found that stone passage rates were 50% in the tamsulosin group and 47% in the placebo group (relative risk, 1.05; 95.8% confidence interval, 0.87 to 1.27; P=.60). No secondary outcomes (time to stone passage, return to work, use of analgesic medication, hospitalization, surgical intervention, and repeated emergency department visit) were significant.
“For emergency department patients who present with renal colic owing to ureteral stones smaller than 9mm, tamsulosin does not appear to promote stone passage,” the authors write. “Guidelines for medical expulsive therapy for urinary stones may need to be revised.”